UK support: Real people answering technical and order questions from a UK inbox
Adults with a body mass index of 27 kg/m 2 or higher and glycated hemoglobin of 7 to 10 percent were randomly assigned to receive once-weekly, subcutaneous tirzepatide (10 or 15 mg) or placebo for 72 weeks (312, 311, and 315, respectively)
In that trial, 4,286 (24.3%) of patients had heart failure with 1,347 of those patients having heart failure with reduced ejection fraction dwarfing the small numbers studied in the initial trials mentioned previously
Tirzepatide generally produces slightly greater average weight loss, but semaglutide is effective for most patients and has a longer track record
WeightSnap has a 30+ peptide and blend library, custom compounds, a reconstitution calculator, and vial inventory, plus a working-or-not verdict